ERBB2 and breast carcinoma: The results presented here should be validated in additional studies with larger sample sizes, which could also shed light on whether there are associations with more diverse breast cancer subtypes (e.g., luminal A, luminal B, Her2-overexpressing, basal) (39, 40) rather than simply classifying tumors as ER positive versus ER negative.